K
K

Dividends • Kazia Therapeutics

KZIA

Kazia Therapeutics Ltd is an oncology-focused biotechnology company, developing anti-cancer drugs. The group is developing paxalisib, a potential treatment for glioblastoma; Cantrixil, being developed for the treatment of ovarian cancer; and Others. The company is also developing EVT801 for the treatment of various tumors. Maximum of revenue is earned from South Korea.

See below the complete and updated table with all dividends paid and declared history, etc

Excluding Date
Payment
Value ($)
Frequency
11/21/2023
12/5/2023
0,063
Quarterly
8/15/2023
8/29/2023
0,063
Quarterly
5/23/2023
6/6/2023
0,063
Quarterly
2/21/2023
3/7/2023
0,063
Quarterly
1/31/2023
-
0
-
11/22/2022
12/6/2022
0,063
Quarterly
8/16/2022
8/30/2022
0,063
Quarterly
5/24/2022
6/7/2022
0,063
Quarterly
2/22/2022
3/8/2022
0,063
Quarterly